CA2358989A1 - Procedes et agents destines a une radiotherapie amelioree - Google Patents
Procedes et agents destines a une radiotherapie amelioree Download PDFInfo
- Publication number
- CA2358989A1 CA2358989A1 CA002358989A CA2358989A CA2358989A1 CA 2358989 A1 CA2358989 A1 CA 2358989A1 CA 002358989 A CA002358989 A CA 002358989A CA 2358989 A CA2358989 A CA 2358989A CA 2358989 A1 CA2358989 A1 CA 2358989A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- agents
- tissue
- radiosensitizer
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 238000001959 radiotherapy Methods 0.000 title description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 122
- 238000011282 treatment Methods 0.000 claims abstract description 94
- 239000002534 radiation-sensitizing agent Substances 0.000 claims abstract description 80
- 230000005865 ionizing radiation Effects 0.000 claims abstract description 31
- 230000005855 radiation Effects 0.000 claims description 74
- 206010028980 Neoplasm Diseases 0.000 claims description 55
- 239000012857 radioactive material Substances 0.000 claims description 34
- 230000002285 radioactive effect Effects 0.000 claims description 19
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 239000003981 vehicle Substances 0.000 claims description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052737 gold Inorganic materials 0.000 claims description 8
- 239000010931 gold Substances 0.000 claims description 8
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 239000002872 contrast media Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 239000000693 micelle Substances 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 5
- 239000008139 complexing agent Substances 0.000 claims description 5
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 claims description 5
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 5
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 claims description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 claims description 4
- 229910052695 Americium Inorganic materials 0.000 claims description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 4
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 4
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical group [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- LXQXZNRPTYVCNG-UHFFFAOYSA-N americium atom Chemical group [Am] LXQXZNRPTYVCNG-UHFFFAOYSA-N 0.000 claims description 4
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 4
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 4
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims description 4
- 150000001541 aziridines Chemical class 0.000 claims description 4
- 229910052788 barium Inorganic materials 0.000 claims description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052797 bismuth Inorganic materials 0.000 claims description 4
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 4
- 229910052796 boron Inorganic materials 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229950004398 broxuridine Drugs 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910017052 cobalt Inorganic materials 0.000 claims description 4
- 239000010941 cobalt Chemical group 0.000 claims description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Chemical group 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960005223 diatrizoic acid Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 4
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 4
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 claims description 4
- 229950006566 etanidazole Drugs 0.000 claims description 4
- 229960005063 gadodiamide Drugs 0.000 claims description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052733 gallium Inorganic materials 0.000 claims description 4
- 229960004716 idoxuridine Drugs 0.000 claims description 4
- 229910052738 indium Inorganic materials 0.000 claims description 4
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical group [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 4
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 claims description 4
- 229960004901 iodamide Drugs 0.000 claims description 4
- 229960001025 iohexol Drugs 0.000 claims description 4
- 229910052741 iridium Inorganic materials 0.000 claims description 4
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 claims description 4
- 229950010514 misonidazole Drugs 0.000 claims description 4
- 150000004957 nitroimidazoles Chemical class 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229910052705 radium Inorganic materials 0.000 claims description 4
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052702 rhenium Inorganic materials 0.000 claims description 4
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 239000010948 rhodium Substances 0.000 claims description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052707 ruthenium Inorganic materials 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 229910052715 tantalum Inorganic materials 0.000 claims description 4
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052713 technetium Inorganic materials 0.000 claims description 4
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 4
- 229910052716 thallium Inorganic materials 0.000 claims description 4
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000001299 aldehydes Chemical class 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- OBISGMNJKBVZBT-UHFFFAOYSA-N ethyl 3,5-diacetamido-2,4,6-triiodobenzoate Chemical compound CCOC(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I OBISGMNJKBVZBT-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 3
- 239000000084 colloidal system Substances 0.000 claims 3
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 claims 3
- 229910052725 zinc Inorganic materials 0.000 claims 3
- 239000011701 zinc Substances 0.000 claims 3
- 150000002825 nitriles Chemical class 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 1
- -1 when distributed Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 59
- 239000000463 material Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000562 conjugate Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000035515 penetration Effects 0.000 description 5
- 238000002725 brachytherapy Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010067623 Radiation interaction Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
L'invention concerne un procédé pour traiter un volume sélectionné de tissu qui consiste à distribuer un agent de sensibilisation aux rayonnements à l'intérieur du volume de tissu pour produire des zones de traitement qui sont généralement réparties de manière uniforme à travers le volume du tissu. L'invention concerne aussi un agent pour traiter ce tissu, l'agent comprenant un agent de sensibilisation aux rayonnements et une source de rayonnement ionisant, utilisés conjointement pour définir un agent de traitement injectable.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23624799A | 1999-01-25 | 1999-01-25 | |
| US09/236,247 | 1999-01-25 | ||
| PCT/US2000/001815 WO2000043045A1 (fr) | 1999-01-25 | 2000-01-25 | Procedes et agents destines a une radiotherapie amelioree |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2358989A1 true CA2358989A1 (fr) | 2000-07-27 |
Family
ID=22888723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002358989A Abandoned CA2358989A1 (fr) | 1999-01-25 | 2000-01-25 | Procedes et agents destines a une radiotherapie amelioree |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1146912A4 (fr) |
| JP (1) | JP2002535291A (fr) |
| KR (1) | KR20020001723A (fr) |
| CN (1) | CN1337886A (fr) |
| AR (1) | AR022404A1 (fr) |
| AU (1) | AU2972500A (fr) |
| BR (1) | BR0007692A (fr) |
| CA (1) | CA2358989A1 (fr) |
| IL (1) | IL144428A0 (fr) |
| WO (1) | WO2000043045A1 (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1710600A (en) * | 1998-10-29 | 2000-05-22 | General Hospital Corporation, The | Enhanced radiation therapy |
| US20020001567A1 (en) | 1998-12-21 | 2002-01-03 | Photogen, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| US8470296B2 (en) | 1998-12-21 | 2013-06-25 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| US6818227B1 (en) | 1999-02-08 | 2004-11-16 | Alza Corporation | Liposome composition and method for administration of a radiosensitizer |
| IL144762A (en) * | 1999-02-08 | 2006-10-31 | Alza Corp | Radiosensitizer liposome preparation, method for its preparation, and its use in the preparation of a drug for radiotherapy |
| EP1206288B1 (fr) * | 1999-08-02 | 2007-01-10 | The Regents Of The University Of Michigan | Effecteurs radiatifs cibles exempts de fibres |
| EP1372742A2 (fr) * | 2000-11-16 | 2004-01-02 | Microspherix LLC | Grain de brachytherapie imageable polymere |
| WO2004026111A2 (fr) | 2000-11-16 | 2004-04-01 | Microspherix Llc | Grain ou fil de curietherapie flexible et/ou elastique |
| US6514193B2 (en) | 2000-11-16 | 2003-02-04 | Microspherix Llc | Method of administering a therapeutically active substance |
| CN101031319A (zh) * | 2003-12-11 | 2007-09-05 | 舍林股份公司 | 改善放射性标记药物的功效的放射增敏剂缀合物 |
| WO2007008232A2 (fr) | 2004-09-03 | 2007-01-18 | Board Of Regents, The University Of Texas System | Ablation locoregionale interne de tissus anormaux par des radionucleides |
| WO2006037081A2 (fr) * | 2004-09-28 | 2006-04-06 | The Regents Of The University Of California | Radiosensibiliseurs a base de nanoparticules |
| WO2006138145A1 (fr) | 2005-06-14 | 2006-12-28 | Northwestern University | Nanoparticules fonctionnalisees d'acide nucleique pour applications therapeutiques |
| KR101488800B1 (ko) | 2007-02-09 | 2015-02-04 | 노오쓰웨스턴 유니버시티 | 세포내 타겟 검출용 입자 |
| CA3055145A1 (fr) | 2007-05-30 | 2008-12-11 | Northwestern University | Nanoparticules fonctionnalisees par des acides nucleiques pour des applications therapeutiques |
| KR101525132B1 (ko) * | 2008-10-08 | 2015-06-02 | 포항공과대학교 산학협력단 | Ｘ 선용 조영제 캡슐 및 이의 제조방법 |
| CN106955360A (zh) | 2008-11-24 | 2017-07-18 | 西北大学 | 多价rna纳米颗粒组合物 |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| US8269197B2 (en) | 2009-07-22 | 2012-09-18 | Intraop Medical Corporation | Method and system for electron beam applications |
| US20120277283A1 (en) * | 2009-08-04 | 2012-11-01 | Mirkin Chad A | Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications |
| CA2779099C (fr) | 2009-10-30 | 2021-08-10 | Northwestern University | Nanoconjugues formes sur matrice |
| CN102933258A (zh) * | 2010-03-01 | 2013-02-13 | 因特奥普医药公司 | 与含氧量低的细胞敏化剂联用的放疗 |
| EP2755692B1 (fr) | 2011-09-14 | 2020-11-25 | Northwestern University | Nanoconjugués capables de traverser la barrière hémato-encéphalique |
| WO2015013673A1 (fr) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Constructions à partir d'acides nucléiques sphériques utilisées en tant qu'agents immunostimulants à des fins prophylactiques et thérapeutiques |
| CA2968531A1 (fr) | 2014-11-21 | 2016-05-26 | Northwestern University | Absorption cellulaire specifique a une sequence de conjugues nanoparticulaires d'acides nucleiques spheriques |
| US20180057888A1 (en) * | 2015-03-13 | 2018-03-01 | The Board Of Regents Of The University Of Texas System | Kub5/hera as a determinant of sensitivity to dna damage |
| WO2018209270A1 (fr) | 2017-05-11 | 2018-11-15 | Northwestern University | Thérapie cellulaire adoptive utilisant des acides nucléiques sphériques (sna) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4490543A (en) * | 1982-11-12 | 1984-12-25 | University Of Northern Iowa Foundation | Low toxicity radiation sensitizer |
| US5342283A (en) * | 1990-08-13 | 1994-08-30 | Good Roger R | Endocurietherapy |
| US5556992A (en) * | 1994-09-02 | 1996-09-17 | Universite De Montreal | Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias |
| US6331286B1 (en) * | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
| US6015541A (en) * | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
-
2000
- 2000-01-24 AR ARP000100289A patent/AR022404A1/es unknown
- 2000-01-25 WO PCT/US2000/001815 patent/WO2000043045A1/fr not_active Ceased
- 2000-01-25 CA CA002358989A patent/CA2358989A1/fr not_active Abandoned
- 2000-01-25 KR KR1020017009307A patent/KR20020001723A/ko not_active Withdrawn
- 2000-01-25 BR BR0007692-9A patent/BR0007692A/pt not_active Application Discontinuation
- 2000-01-25 JP JP2000594498A patent/JP2002535291A/ja active Pending
- 2000-01-25 AU AU29725/00A patent/AU2972500A/en not_active Abandoned
- 2000-01-25 CN CN00803059A patent/CN1337886A/zh active Pending
- 2000-01-25 EP EP00908366A patent/EP1146912A4/fr not_active Withdrawn
- 2000-01-25 IL IL14442800A patent/IL144428A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002535291A (ja) | 2002-10-22 |
| EP1146912A1 (fr) | 2001-10-24 |
| BR0007692A (pt) | 2001-11-06 |
| CN1337886A (zh) | 2002-02-27 |
| KR20020001723A (ko) | 2002-01-09 |
| AR022404A1 (es) | 2002-09-04 |
| IL144428A0 (en) | 2002-05-23 |
| AU2972500A (en) | 2000-08-07 |
| WO2000043045A1 (fr) | 2000-07-27 |
| EP1146912A4 (fr) | 2003-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2358989A1 (fr) | Procedes et agents destines a une radiotherapie amelioree | |
| JP3735770B2 (ja) | 高エネルギ光線治療薬剤 | |
| Choi et al. | Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme | |
| US8033977B2 (en) | Methods of enhancing radiation effects with metal nanoparticles | |
| US6576257B1 (en) | Targeted drug activation | |
| US6562316B1 (en) | Drug delivery system with two-step targeting | |
| EP1131100B1 (fr) | Compositions au traitement de troubles metaboliques osseux et de metastases osseuses contenant un agent photosensitive et un bisphosphonate | |
| KR20130019029A (ko) | 병용요법을 위한 방사핵종 및 세포독성제를 봉입한 리포좀 | |
| US20170173364A1 (en) | Nanoparticle-mediated ablation of glioblastoma and of other malignancies | |
| Schaffer et al. | Porphyrins as radiosensitizing agents for solid neoplasms | |
| KR102698260B1 (ko) | 산화철 자성 입자를 포함하는 간암치료용 조성물 | |
| US7384623B1 (en) | High energy phototherapeutic agents | |
| MXPA01007487A (es) | Metodo para terapia de radiacion mejorada | |
| US12329831B2 (en) | Radionuclide-loaded nanoparticles for focal tissue ablation | |
| WO1998047539A1 (fr) | Compose d'imagerie rmv | |
| US8709380B1 (en) | Targeting agents for enhancing radiation therapy | |
| KR20050025933A (ko) | 방사성물질-키토산 복합체를 함유하는 전립선암 치료용조성물 및 조성물 제조용 키트 | |
| Ponchelle et al. | 177Lu‐Gold Nanohybrids in Radiotherapeutic Approaches Against Cancer | |
| Tng et al. | Nanoparticles for Enhanced Radiotherapy and Imaging Applications | |
| Govender et al. | Exogenous Dual/Multi-Responsive Delivery Nanoplatforms in Cancer Theranostics | |
| MXPA01006368A (en) | High energy phototherapeutic agents | |
| MXPA99000100A (en) | Novelty radiopharmaceutical compositions and matrices and uses of mis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |